Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.71 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238943 | 1.00 | OPRL1 (0.79) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL2242983 | 0.91 | OPRL1 (0.85) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL2242979 | 0.91 | OPRL1 (0.85) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL2242815 | 0.89 | OPRL1 (0.77) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL1711157 | 0.89 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL25736629 | 0.89 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL1711153 | 0.89 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL2242811 | 0.89 | OPRL1 (0.77) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL29408438 | 0.89 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL3585205 | 0.87 | OPRL1 (0.62) | OPRL1OPRM1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069382-A1 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2089030-A2 | AGENT FOR PROPHYLAXIS OR TREATMENT OF ALCOHOL DEPENDENCE OR DRUG DEPENDENCE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-08-19 | — | — | EP | claimed |
| WO-2008050698-A2 | AGENT FOR PROPHYLAXIS OR TREATMENT OF ALCOHOL DEPENDENCE OR DRUG DEPENDENCE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-02 | — | — | WO | claimed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8207201-B2 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8003669-B2 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100069382-A1 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090253747-A1 | Remedy for sleep disturbance | TESHIMA KOJI | 2009-10-08 | — | — | US | disclosed |
| EP-2089030-A2 | AGENT FOR PROPHYLAXIS OR TREATMENT OF ALCOHOL DEPENDENCE OR DRUG DEPENDENCE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7566728-B2 | Advance circadian rhythm disorders; using opioid receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-28 | — | — | US | disclosed |
| WO-2008050698-A2 | AGENT FOR PROPHYLAXIS OR TREATMENT OF ALCOHOL DEPENDENCE OR DRUG DEPENDENCE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-02 | — | — | WO | disclosed |
| US-20050119308-A1 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069382-A1 | Agent for prophylaxis or treatment of alcohol dependence or drug dependence | ADH1A, ADH1C, ADH5 | OPRL1 292/4885OPRM1 13/4885OPRK1 24/4885 |
| US-20050119308-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
| US-20090253747-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.